Axogen Incorporated (NASDAQ:AXGN) on Focus After Report of Less Shorts

December 7, 2017 - By Vivian Currie

 Axogen Incorporated (NASDAQ:AXGN) on Focus After Report of Less Shorts

The stock of Axogen Incorporated (NASDAQ:AXGN) registered a decrease of 9.61% in short interest. AXGN’s total short interest was 960,000 shares in December as published by FINRA. Its down 9.61% from 1.06M shares, reported previously. With 199,700 shares average volume, it will take short sellers 5 days to cover their AXGN’s short positions. The short interest to Axogen Incorporated’s float is 4.16%.

The stock increased 1.34% or $0.35 during the last trading session, reaching $26.45. About 338,153 shares traded or 19.22% up from the average. AxoGen, Inc. (NASDAQ:AXGN) has risen 181.49% since December 7, 2016 and is uptrending. It has outperformed by 164.79% the S&P500.

AxoGen, Inc. provides surgical solutions for peripheral nerve injuries. The company has market cap of $901.78 million. The companyÂ’s surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. It currently has negative earnings. The Company’s solutions also comprise Avive Soft Tissue Membrane, a minimally processed human umbilical cord membrane that is used as a resorbable soft tissue covering to separate tissues and modulate inflammation in the surgical bed.

AxoGen, Inc. (NASDAQ:AXGN) Ratings Coverage

Among 7 analysts covering AxoGen (NASDAQ:AXGN), 7 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. AxoGen had 16 analyst reports since August 11, 2015 according to SRatingsIntel. The stock of AxoGen, Inc. (NASDAQ:AXGN) has “Buy” rating given on Monday, August 21 by Cantor Fitzgerald. The firm earned “Buy” rating on Tuesday, November 22 by Lake Street. Wedbush maintained the stock with “Buy” rating in Tuesday, November 21 report. The firm has “Hold” rating by Lake Street given on Thursday, November 3. Roth Capital maintained AxoGen, Inc. (NASDAQ:AXGN) on Monday, September 11 with “Buy” rating. The stock has “Outperform” rating by Leerink Swann on Tuesday, November 21. The firm has “Outperform” rating given on Friday, August 28 by Wedbush. As per Tuesday, August 11, the company rating was upgraded by Zacks. As per Monday, November 7, the company rating was maintained by Wedbush. The firm earned “Outperform” rating on Thursday, November 2 by Leerink Swann.

More recent AxoGen, Inc. (NASDAQ:AXGN) news were published by: Streetinsider.com which released: “Jefferies Starts AxoGen, Inc. (AXGN) at Buy, Best Growth Story in Medtech” on November 30, 2017. Also Streetinsider.com published the news titled: “AxoGen, Inc. (AXGN) PT Raised to $27 at JMP Securities Following Analyst Day” on November 21, 2017. Nasdaq.com‘s news article titled: “AxoGen, Inc. to Present at the 29th Annual Piper Jaffray Healthcare Conference” with publication date: November 14, 2017 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.